Although Pap smear screening has reduced cervical cancer incidence in the United States, cervical cancer continues to be associated with substantial morbidity and mortality, contributes to racial and ethnic disparities, and Imposes high economic costs. Advances in cancer epidemiology and medical technology provide a remarkable opportunity to improve upon the effectiveness and efficiency of the cervical cancer screening process. However, critical challenges remain with respect to clinical decision making and adoption of best practices, pertaining to patient behavior, provider incentives, health systems, and the real-world clinical effectiveness of emerging technologies. We propose to employ a decision-analytic approach, adapting an existing modeling framework by leveraging data from clinical provider networks and a state-of-the-art registry of cervical cancer Information in New Mexico; evaluate and weigh the tradeoffs (benefits and harms) of alternative cervical interventions across the continuum of care; explore the uncertainty around their outcomes; incorporate information on patient behavior and real-world practice; and inform timely clinical and policy questions. By achieving our specific aims, we expect to have an impact on (1) the effectiveness and efficiency of the cervical cancer screening process by investigating the effects of acceptability, delivery, and adoption of best practices; (2) cervical cancer outcomes, including reduced incidence, enhanced quality of life through earlier detection, improved survival, and reduced disparities; (3) the equitable distribution and rationale use of new technology; and (4) the financial and economic profile of health care organizations related to cervical cancer control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA164336-02
Application #
8555414
Study Section
Special Emphasis Panel (ZCA1-SRLB-R (O1))
Project Start
2011-09-23
Project End
2016-05-31
Budget Start
2012-09-01
Budget End
2013-05-31
Support Year
2
Fiscal Year
2012
Total Cost
$251,242
Indirect Cost
$38,831
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Kamineni, Aruna; Tiro, Jasmin A; Beaber, Elisabeth F et al. (2018) Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer :
Doubeni, Chyke A; Gabler, Nicole B; Wheeler, Cosette M et al. (2018) Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 68:199-216
Castle, Philip E; Wheeler, Cosette M; Campos, Nicole G et al. (2018) Inefficiencies of over-screening and under-screening for cervical cancer prevention in the U.S. Prev Med 111:177-179
McDonald, Yolanda J; Schwind, Michael; Goldberg, Daniel W et al. (2017) An analysis of the process and results of manual geocode correction. Geospat Health 12:526
Cuzick, Jack; Myers, Orrin; Lee, Ji-Hyun et al. (2017) Outcomes in Women With Cytology Showing Atypical Squamous Cells of Undetermined Significance With vs Without Human Papillomavirus Testing. JAMA Oncol 3:1327-1334
McDonald, Yolanda J; Goldberg, Daniel W; Scarinci, Isabel C et al. (2017) Health Service Accessibility and Risk in Cervical Cancer Prevention: Comparing Rural Versus Nonrural Residence in New Mexico. J Rural Health 33:382-392
Haas, Jennifer S; Sprague, Brian L; Klabunde, Carrie N et al. (2016) Provider Attitudes and Screening Practices Following Changes in Breast and Cervical Cancer Screening Guidelines. J Gen Intern Med 31:52-9
Gage, Julia C; Hunt, William C; Schiffman, Mark et al. (2016) Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program. Cancer Epidemiol Biomarkers Prev 25:36-42
Tosteson, Anna N A; Beaber, Elisabeth F; Tiro, Jasmin et al. (2016) Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med 31:372-9

Showing the most recent 10 out of 31 publications